Latest Nilotinib Stories
While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.
Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online [date] in the Journal of the National Cancer Institute.
A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start.
Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies.
NEW YORK, Dec.
NEW YORK, Dec. 6, 2010 /PRNewswire/ -- Pfizer Inc.
EAST HANOVER, N.J., Dec.
NEW YORK, Dec. 3, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients.
Patients with rare type of leukemia now have another treatment option SILVER SPRING, Md., Oct. 28 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed.
COLUMBUS, Ohio, Aug. 24 /PRNewswire/ -- Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.